Amid plunging stock values, Valeant Pharmaceuticals International Inc. has named Christina Ackermann as executive vice president and general counsel to lead the company through its legal and regulatory problems.

“This is a very exciting time to be joining Valeant,” Ackermann said in a press release. “The company has many attractive opportunities as well as some challenges, which I look forward to working through with my colleagues.”